Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Volunteers. Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Platelet Function and Safety After IV and Oral Diclofenac, IV Ketorolac and Oral Aspirin in Adult Volunteers

NCT00548678
View directory record Official record
Conditions
Healthy
Interventions
intravenous diclofenac sodium (DIC075V), ketorolac, oral diclofenac (Cataflam), aspirin
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2008 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects

NCT00866463
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

NCT05238493
View directory record Official record
Conditions
Healthy Volunteers
Interventions
VEL-101, Placebo
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 27, 2026, 5:01 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

MLN3126 Single Rising Dose Study

NCT02447458
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MLN3126, MLN3126 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

NCT03564158
View directory record Official record
Conditions
Healthy
Interventions
meropenem-vaborbactam, Placebo, Moxifloxacin
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 27, 2026, 5:01 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males

NCT02072993
View directory record Official record
Conditions
Healthy Subjects
Interventions
AZD1979, Placebo to match
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant

NCT01122784
View directory record Official record
Conditions
Plague Vaccine
Interventions
rF1V vaccine (with Adjuvant), rF1V vaccine (without Adjuvant)
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
11
States / cities
San Francisco, California • Santa Ana, California • Lenexa, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Pecan Nut Snacks v Equicaloric Snacks on Appetite, Food Intake, Metabolism, Hormones and Biomarkers

NCT04484974
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Pecan snack, Tortilla chip snack
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Black Raspberry Phytochemicals on Oral Microbiome in Current Smokers and Non-smokers

NCT02439255
View directory record Official record
Conditions
Healthy Subject, Tobacco Use Disorder
Interventions
Laboratory Biomarker Analysis, Phytochemical, Placebo, Screening Questionnaire Administration
Other · Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 50 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 27, 2026, 5:01 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent

NCT07723118
View directory record Official record
Conditions
Healthy Participants
Interventions
Adagrasib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

NCT01013610
View directory record Official record
Conditions
Mild Alzheimer's Disease
Interventions
LNK-754, Placebo
Drug
Lead sponsor
Link Medicine Corporation
Industry
Eligibility
55 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
7
States / cities
Phoenix, Arizona • Long Beach, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Sep 27, 2026, 5:01 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Imaging Techniques in CT: Technical Development

NCT02242448
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
45 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 27, 2026, 5:01 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

NCT07075640
View directory record Official record
Conditions
Healthy Participants
Interventions
AG-236, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of DISC-3405 in Healthy Volunteers

NCT06050915
View directory record Official record
Conditions
Healthy Volunteer
Interventions
DISC-3405, Placebo
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage

NCT02231190
View directory record Official record
Conditions
Tendon Injuries
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 27, 2026, 5:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Study: Effects of G-CSF on T Cell Function

NCT00039650
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Abemaciclib in Healthy Participants

NCT02672423
View directory record Official record
Conditions
Healthy
Interventions
Abemaciclib Capsules (Reference Formulation), Abemaciclib Tablet (Test Formulation)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

NCT05045638
View directory record Official record
Conditions
Healthy Participants
Interventions
Rosuvastatin, Sotorasib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

NCT06491550
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis

NCT01250990
View directory record Official record
Conditions
Dyslipidemias
Interventions
Niacin, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg

NCT00649558
View directory record Official record
Conditions
Healthy
Interventions
Pioglitazone HCl Tablets 45 mg, Actos® Tablets 45 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

NCT01259115
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine transdermal patch, Ketoconazole tablet, Placebo to match ketoconazole tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 54 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 27, 2026, 5:01 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

NCT00780325
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CG100649 (2 mg), Celecoxib, Placebo capsules, Naproxen, Acetazolamide, CG100649 (8 mg)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 27, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

NCT06094738
View directory record Official record
Conditions
Healthy
Interventions
Relacorilant under fasted conditions, Relacorilant after a high-fat meal, Relacorilant after a low-fat meal
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 27, 2026, 5:01 PM EDT